Moneycontrol PRO
Upcoming Webinar:Watch a panel of experts discuss: Challenges of continuously evolving regulation for Cryptocurrency, on 7th July at 3pm. Register Now
you are here: HomeNewsIndia

Some evidence shows children could be COVID-19 spreaders: ICMR

Speaking on the coronavirus infection spread in the country among children, ICMR Director General Balram Bhargava said tat overall the figure in India is that below the age of 17 years, only 8 percent are COVID-19 positive.

October 28, 2020 / 08:22 PM IST

There is some evidence which shows that children who were earlier thought to be protected against coronavirus infection can be "spreaders, rather than super-spreaders”, ICMR Director General Balram Bhargava said on Tuesday.

Speaking on the coronavirus infection spread in the country among children, Bhargava said tat overall the figure in India is that below the age of 17 years, only 8 percent are COVID-19 positive.

"Below five years, the figure would probably be less than a per cent but then we can come back with a figure for this,” he said.

In response to a question over surge in cases among children in Mizoram, there are 315 active coronavirus cases in the state as on date.

Over Kawasaki disease and presumably a link with COVID-19, Bhargava said India so far has not reported any cases of Kawasaki disease among COVID-19 patients.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Kawasaki is an auto-immune disease that affects children who are less than five years of age and presents with fever, Thrombocytosis and a condition in which the arteries of the heart become dilated and aneurysm.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

So this is a rare condition which affects more males than females.

The disease is more common in the US and less common in India, Bhargava said at a press briefing.

"This has been described with COVID-19 in different parts of the world. I don’t think we have had any experience of Kawasaki with COVID-19 in India so far. It is a very rare condition."

"Having said that we have to remember that it affects small children and the arteries of the heart get dilated and clots can form in that and it can lead to heart attacks and can also be harmful for the child,” he said.

Follow our full coverage of the coronavirus pandemic here.
first published: Oct 28, 2020 12:43 pm
ISO 27001 - BSI Assurance Mark